MedTrace Logo

Evaluation of AppleX™ Apple Extract on Anti-Inflammatory and Healthy Aging Effects

NCT07678346 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2026-07-01

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if AppleX™ Apple Extract can help lower systemic inflammation in adults aged 45-70 with signs of low-grade inflammation. It will also look at the extract's effects on fatigue, joint comfort, and biological aging metrics.

The main questions it aims to answer are:

* Does taking AppleX™ Apple Extract daily lower high-sensitivity C-reactive protein (hsCRP) levels, a key marker of inflammation in the blood?
* Does AppleX™ Apple Extract improve participant-reported fatigue and joint comfort?
* Does the extract slow down biological or epigenetic aging metrics compared to a placebo?

Researchers will compare AppleX™ Apple Extract to a placebo (a look-alike capsule that contains no active ingredients) to see if the apple extract has a measurable anti-inflammatory and healthy aging effect.

Conditions

  • Systemic Inflammation (hsCRP)
  • Healthy Aging
  • Vitality
  • Healthy Adult Participants

Interventions

DIETARY_SUPPLEMENT

Apple Extract

A whole-apple extract standardized to 15% fisetin within a natural polyphenol matrix of quercetin, chlorogenic acid, and procyanidins. Administered as a 100 mg capsule taken orally once daily with breakfast for 24 weeks.

OTHER

Placebo

An identical, matching inactive look-alike capsule containing microcrystalline cellulose. Administered orally once daily with breakfast for 24 weeks.

Sponsors & Collaborators

  • Alethios, Inc.

    collaborator INDUSTRY

  • Nutraland USA, Inc.

    lead INDUSTRY

Principal Investigators

  • Dr. Bill Clark, PhD · Natprologix, LLC

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-07-31
Primary Completion
2027-01-31
Completion
2027-02-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07678346 on ClinicalTrials.gov